TELA Bio, Inc.: NORTH RUN CAPITAL, LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
North Run Capital, LP amended its Schedule 13G filing on TELA Bio, Inc., updating its beneficial ownership stake with the SEC under accession number 0001193125-26-460552. The amendment signals a change in the investment firm's position in the medical device maker, though the filing did not disclose the specific size of the stake or the direction of the change. Investors monitor 13G amendments for insight into institutional sentiment toward small-cap healthcare names like TELA Bio. What to watch next is whether North Run's revised position reflects accumulation or reduction, and whether other institutional holders follow suit in upcoming filings.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
TELA Bio, Inc., North Run Capital, LP